Document is current

Article History

Received: 23 July 2024

Accepted: 1 December 2024

First Online: 5 December 2024

Declarations

:

: The study protocol was approved by the ethics committee of the Charité University Medicine Berlin, Germany (EA4/123/21). Participants gave written informed consent to participate in the study prior to enrolment.

: No applicable.

: RR: Support for attending meetings and/or travel: AlfaSigma, Lilly, UCB; All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.): RABBIT* is supported by a joint, unconditional grant from AbbVie, Amgen, BMS, Celltrion, Fresenius Kabi, Galapagos, Hexal, Lilly, MSD, Pfizer, Samsung Bioepis, Sanofi Aventis, Viatris Sante, and UCB, and previously Roche. TR: no competing interest. RA: Consulting fees: Abbvie, AlfaSigma, Amgen, Biogen, BMS, Celltrion, Chugai, Galapagos, Gilead, Hexal, Janssen, Lilly, Mylan/Viatris, Novartis, Pfizer, Roche, UCB; Payment or honoraria for speakers bureaus or similar: Abbvie, AlfaSigma, Amgen, Biogen, BMS, Celltrion, Chugai, Galapagos, Gilead, Hexal, Janssen, Lilly, Mylan/Viatris, Novartis, Pfizer, Roche, UCB; Support for attending meetings and/or travel: Abbvie, AlfaSigma, Amgen, Biogen, BMS, Celltrion, Chugai, Galapagos, Gilead, Hexal, Janssen, Lilly, Mylan/Viatris, Novartis, Pfizer, Roche, UCB. AK: Consulting fees: AbbVie, Gilead, Boehringer Ingelheim, Novartis, Janssen, UCB, Lilly; Payment or honoraria for speakers bureaus or similar: AbbVie, Gilead, Boehringer Ingelheim, Roche, Novartis, Janssen, UCB, Lilly; Support for attending meetings and/or travel: AbbVie, Boehringer Ingelheim; Participation on a Data Safety Monitoring Board or Advisory Board: Pfizer; Leadership or fiduciary role: German society for rheumatology. MSchneider: Grants or contracts from any entity: GSK, AstraZeneca; Consulting fees: AstraZeneca, GSK, Otsuka, UCB; Payment or honoraria for speakers bureaus or similar: AstraZeneca, Pfizer, GSK, BMS; Support for attending meetings and/or travel: Abbvie; Leadership or fiduciary role: Guidelines DGRh. MSchaefer: Grants or contracts from any entity: PI of the RABBIT* registry. AS: Grants or contracts from any entity: PI of the RABBIT* registry; Honoraria for lectures: AbbVie, Pfizer, Galapagos, Takeda, Janssen, Lilly, Samsung Bioepis; Participation on a Data Safety Monitoring Board or Advisory Board: Unpaid role as DMC-Chair of the BADBIR register, UK, Unpaid member of the DMC Board of the Lupus Best Study. YM: Honoraria for lectures: Lilly, Pfizer.